Identification of driver genes associated with chemotherapy resistance of Ewing's sarcoma.

BACKGROUND

The aim of this study was to identify the driver genes associated with chemotherapy resistance of Ewing's sarcoma and potential targets for Ewing's sarcoma treatment.

METHODS

Two mRNA microarray datasets, GSE12102 and GSE17679, were downloaded from the Gene Expression Omnibus database, which contain 94 human Ewing's sarcoma samples, including 65 from those who experienced a relapse and 29 from those with no evidence of disease. The differen tially expressed genes (DEGs) were identified using LIMMA package R. Subsequently, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed for DEGs using Database for Annotation, Visualization and Integrated Analysis. The protein-protein interaction network was constructed using Cytoscape software, and module analysis was performed using Molecular Complex Detection.

RESULTS

A total of 206 upregulated DEGs and 141 downregulated DEGs were identified. Upregulated DEGs were primarily enriched in DNA replication, nucleoplasm and protein kinase binding for biological processes, cellular component and molecular functions, respectively. Downregulated DEGs were predominantly involved in receptor clustering, membrane raft, and ligand-dependent nuclear receptor binding. The protein-protein interaction network of DEGs consisted of 150 nodes and 304 interactions. Thirteen hub genes were identified, and biological analysis revealed that these genes were primarily enriched in cell division, cell cycle, and mitosis. Furthermore, based on closeness centrality, betweenness centrality, and degree centrality, the three most significant genes were identified as , , and . Furthermore, the significant network module was composed of nine genes. These genes were primarily enriched in mitotic nuclear division, mitotic chromosome condensation, and nucleoplasm.

CONCLUSION

These hub genes, especially , , and , may be closely associated with the progression of Ewing's sarcoma chemotherapy resistance, and further experiments are needed for confirmation.